JP2003505343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505343A5 JP2003505343A5 JP2001501237A JP2001501237A JP2003505343A5 JP 2003505343 A5 JP2003505343 A5 JP 2003505343A5 JP 2001501237 A JP2001501237 A JP 2001501237A JP 2001501237 A JP2001501237 A JP 2001501237A JP 2003505343 A5 JP2003505343 A5 JP 2003505343A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum
- complex
- counterpart
- medicament
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19925739A DE19925739A1 (de) | 1999-06-07 | 1999-06-07 | Therapeutikum mit einem Botulinum-Neurotoxin |
| DE19925739.6 | 1999-06-07 | ||
| PCT/DE2000/001777 WO2000074703A2 (de) | 1999-06-07 | 2000-05-26 | Therapeutikum mit einem botulinum-neurotoxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007130686A Division JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505343A JP2003505343A (ja) | 2003-02-12 |
| JP2003505343A5 true JP2003505343A5 (enExample) | 2007-06-28 |
Family
ID=7910318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001501237A Pending JP2003505343A (ja) | 1999-06-07 | 2000-05-26 | ボツリヌス神経毒を含む治療薬 |
| JP2007130686A Withdrawn JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007130686A Withdrawn JP2007238627A (ja) | 1999-06-07 | 2007-05-16 | ボツリヌス神経毒を含む治療薬 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7964199B1 (enExample) |
| EP (1) | EP1185291B2 (enExample) |
| JP (2) | JP2003505343A (enExample) |
| KR (1) | KR100466407B1 (enExample) |
| CN (2) | CN101062009A (enExample) |
| AR (1) | AR024306A1 (enExample) |
| AT (1) | ATE258803T1 (enExample) |
| AU (1) | AU774590B2 (enExample) |
| CA (1) | CA2376193C (enExample) |
| CO (1) | CO5170431A1 (enExample) |
| CZ (1) | CZ20014351A3 (enExample) |
| DE (3) | DE19925739A1 (enExample) |
| DK (1) | DK1185291T3 (enExample) |
| EA (1) | EA004202B1 (enExample) |
| ES (1) | ES2215056T5 (enExample) |
| GE (1) | GEP20043200B (enExample) |
| HU (1) | HUP0201530A3 (enExample) |
| IL (2) | IL146974A0 (enExample) |
| MX (1) | MXPA01012540A (enExample) |
| NO (1) | NO20015964L (enExample) |
| PL (1) | PL198958B1 (enExample) |
| PT (1) | PT1185291E (enExample) |
| TW (1) | TWI251492B (enExample) |
| UA (1) | UA72253C2 (enExample) |
| WO (1) | WO2000074703A2 (enExample) |
| ZA (1) | ZA200110074B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| EP1491205A4 (en) * | 2002-03-29 | 2007-04-25 | Chemo Sero Therapeut Res Inst | MEANS FOR THE TREATMENT OF HYPERMYOTONIA |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| EP2272340B1 (en) * | 2002-08-19 | 2018-03-14 | Ira Sanders | Botulinum toxin |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| ZA200506715B (en) * | 2003-03-06 | 2007-05-30 | Botulinum Toxin Res Ass Inc | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
| US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| WO2004112821A1 (ja) * | 2003-06-20 | 2004-12-29 | Santen Pharmaceutical Co., Ltd. | 筋緊張亢進性疾患の治療剤 |
| US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| JP2007527431A (ja) | 2004-03-03 | 2007-09-27 | ルバンス セラピュティックス | 局所的診断及び治療用の輸送のための組成物及び方法 |
| ES2691498T3 (es) | 2004-03-03 | 2018-11-27 | Revance Therapeutics, Inc. | Aplicación tópica y liberación transdérmica de toxinas botulínicas |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| CA2578250C (en) * | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
| US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| CN101027083A (zh) * | 2004-09-27 | 2007-08-29 | 莫茨药物股份两合公司 | 梭状芽孢杆菌神经毒素在组织愈合中的用途 |
| EP1861112A4 (en) | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES |
| KR20070116710A (ko) * | 2005-03-03 | 2007-12-11 | 알러간, 인코포레이티드 | 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스 |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| HRP20090382T1 (hr) * | 2005-06-17 | 2009-09-30 | Merz Pharma Gmbh & Co.Kgaa | Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom |
| CA2629499A1 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| MX2009012990A (es) * | 2007-06-01 | 2010-04-01 | Merz Pharma Gmbh & Co Kgaa | Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. |
| DE102007038015A1 (de) | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| JP5432727B2 (ja) * | 2008-01-29 | 2014-03-05 | 株式会社抗体研究所 | Ａ型ボツリヌス毒素中和組成物及びヒト抗ａ型ボツリヌス毒素抗体 |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| EP4588519A3 (en) * | 2008-03-14 | 2025-10-15 | Allergan, Inc. | Immuno-based botulinum toxin serotype a activity assays |
| US20110033431A1 (en) * | 2008-03-31 | 2011-02-10 | The Chemo-Sero-Therapeutic Research Institute | Type a2 botulinum toxin preparation |
| CA2733283A1 (en) | 2008-08-29 | 2010-03-04 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
| ES2426667T3 (es) | 2008-09-09 | 2013-10-24 | Susanne Grafe | Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano) |
| CN101386648B (zh) * | 2008-09-25 | 2012-05-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途 |
| CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| PL2490986T3 (pl) * | 2009-10-21 | 2019-03-29 | Revance Therapeutics, Inc. | Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| EP2627318B1 (en) | 2010-10-12 | 2017-08-16 | Merz Pharma GmbH & Co. KGaA | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| US9050337B2 (en) * | 2011-06-27 | 2015-06-09 | Sang Duck Kim | Method for treating atrophic skin scars using a mixture of botulinum toxin and air |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| KR102272580B1 (ko) * | 2013-07-30 | 2021-07-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도 |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| ES2762951T3 (es) * | 2015-04-24 | 2020-05-26 | Consiglio Nazionale Ricerche | Nuevo uso terapéutico de la neurotoxina botulínica serotipo A |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| RU2762607C2 (ru) | 2016-09-13 | 2021-12-21 | Аллерган, Инк. | Стабилизированные небелковые композиции клостридиального токсина |
| KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| EP3600221A4 (en) * | 2017-03-22 | 2021-01-13 | Bonti, Inc. | BOTULINARY NEUROTOXINS FOR USE IN THERAPY |
| IL268688B2 (en) | 2017-03-24 | 2024-01-01 | Merz Pharma Gmbh & Co Kgaa | Improved use of botulinum toxin to treat sialorrhea |
| WO2020047159A1 (en) | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
| EP3860640A1 (en) | 2018-10-02 | 2021-08-11 | Merz Pharma GmbH & Co. KGaA | Novel uses of botulinum neurotoxin for treating lipoedema |
| IL285634B2 (en) | 2019-02-21 | 2025-06-01 | Merz Pharma Gmbh Co Kgaa | Novel uses of botulinum neurotoxin for the treatment of tremor |
| US20230329996A1 (en) | 2020-06-05 | 2023-10-19 | Merz Pharma Gmbh & Co. Kgaa | High dose and low volume botulinum toxin treatment of facial wrinkles |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| CN120379640A (zh) | 2022-11-28 | 2025-07-25 | 莫茨药物股份两合公司 | 用于颈部年轻化的高浓度肉毒杆菌毒素治疗 |
| AU2023400491A1 (en) | 2022-11-28 | 2025-04-10 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin injection in platysma for lower face and neck rejuvenation |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
| AU2024274999A1 (en) | 2023-05-23 | 2025-11-13 | Merz Therapeutics GmbH | Botulinum toxin for treating peripheral neuropathic pain |
| AU2024288687A1 (en) | 2023-07-12 | 2025-10-23 | Merz Pharma Gmbh & Co. Kgaa | Treatment of hyperpigmentation conditions by botulinum toxin |
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE286405T1 (de) | 1993-05-14 | 2005-01-15 | Stephen S Arnon | Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen |
| CA2164626C (en) * | 1993-06-10 | 2004-11-23 | K. Roger Aoki | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| EP1790352B1 (en) | 1993-12-28 | 2008-07-09 | Allergan, Inc. | Use of botulinum toxin for the manufacture of a medicament for reducing low back pain |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| WO1996005222A1 (en) | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| WO1996039167A1 (en) * | 1995-06-06 | 1996-12-12 | Pearce L Bruce | Improved compositions and methods for chemodenervation using neurotoxins |
| US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| EP1475099B2 (en) * | 1997-07-15 | 2014-04-09 | The Regents of the University of Colorado | Use of botulinum toxin to treat urinary incontinence |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| MX2011013014A (es) * | 2009-07-02 | 2012-01-27 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas que exhiben actividad biologica acortada. |
-
1999
- 1999-06-07 DE DE19925739A patent/DE19925739A1/de not_active Withdrawn
-
2000
- 2000-05-26 CN CNA2007101102394A patent/CN101062009A/zh active Pending
- 2000-05-26 DE DE10081516T patent/DE10081516D2/de not_active Ceased
- 2000-05-26 KR KR10-2001-7015668A patent/KR100466407B1/ko not_active Expired - Fee Related
- 2000-05-26 AT AT00943666T patent/ATE258803T1/de active
- 2000-05-26 US US10/018,373 patent/US7964199B1/en not_active Expired - Lifetime
- 2000-05-26 PT PT00943666T patent/PT1185291E/pt unknown
- 2000-05-26 ES ES00943666T patent/ES2215056T5/es not_active Expired - Lifetime
- 2000-05-26 CZ CZ20014351A patent/CZ20014351A3/cs unknown
- 2000-05-26 CA CA002376193A patent/CA2376193C/en not_active Expired - Fee Related
- 2000-05-26 DK DK00943666T patent/DK1185291T3/da active
- 2000-05-26 CN CNB008086419A patent/CN100389820C/zh not_active Expired - Fee Related
- 2000-05-26 EP EP00943666A patent/EP1185291B2/de not_active Expired - Lifetime
- 2000-05-26 HU HU0201530A patent/HUP0201530A3/hu unknown
- 2000-05-26 IL IL14697400A patent/IL146974A0/xx active IP Right Grant
- 2000-05-26 AU AU58047/00A patent/AU774590B2/en not_active Ceased
- 2000-05-26 UA UA2002010181A patent/UA72253C2/uk unknown
- 2000-05-26 MX MXPA01012540A patent/MXPA01012540A/es active IP Right Grant
- 2000-05-26 WO PCT/DE2000/001777 patent/WO2000074703A2/de not_active Ceased
- 2000-05-26 DE DE50005208T patent/DE50005208D1/de not_active Expired - Lifetime
- 2000-05-26 GE GEAP20006278A patent/GEP20043200B/en unknown
- 2000-05-26 JP JP2001501237A patent/JP2003505343A/ja active Pending
- 2000-05-26 EA EA200200017A patent/EA004202B1/ru not_active IP Right Cessation
- 2000-05-26 PL PL352468A patent/PL198958B1/pl not_active IP Right Cessation
- 2000-06-07 CO CO00042309A patent/CO5170431A1/es not_active Application Discontinuation
- 2000-06-07 AR ARP000102818A patent/AR024306A1/es unknown
- 2000-08-24 TW TW089111212A patent/TWI251492B/zh not_active IP Right Cessation
-
2001
- 2001-12-06 ZA ZA200110074A patent/ZA200110074B/xx unknown
- 2001-12-06 IL IL146974A patent/IL146974A/en not_active IP Right Cessation
- 2001-12-06 NO NO20015964A patent/NO20015964L/no unknown
-
2007
- 2007-05-16 JP JP2007130686A patent/JP2007238627A/ja not_active Withdrawn
-
2011
- 2011-05-11 US US13/068,439 patent/US20110217287A1/en not_active Abandoned
- 2011-11-23 US US13/303,973 patent/US8398998B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505343A5 (enExample) | ||
| CY2020003I1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| AT500379B1 (de) | Tau-proteine | |
| CY1110128T1 (el) | Καταλυτικα μονοκλωνικα αντισωματα με δραστικοτητα πρωτεασης για την εκλεκτικη λυση του πρωτεϊνικου συστατικου των πλακων και συνονθυλευματων που σχετιζονται με παθολογικες καταστασεις | |
| ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| WO2002003911A8 (en) | Prevention and treatment of alzheimer's disease | |
| WO2001089457A3 (en) | Thrombopoietin mimetics | |
| WO2002094228A8 (en) | Prevention and treatment of allergies by helminthic regulation of ige | |
| CY1107609T1 (el) | Απεικoνιση, διaγνωση και θεραπεiα ασθeνειας | |
| JP2001515920A5 (enExample) | ||
| ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
| EP1610678A4 (en) | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF FOR INHIBITING THE ACTIVITY OF METAL PROTEINS | |
| ATE310088T1 (de) | Behandlung und nachweis von staphylokokkeninfektionen | |
| WO2001068801A3 (en) | SINGLE CHAIN ANTIBODY AGAINST MUTANT p53 | |
| JP2003533188A5 (enExample) | ||
| WO2007021886A3 (en) | Truncated memapsin 2 for use for treating alzheimer's disease | |
| ATE369429T1 (de) | Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen | |
| WO2002055560A3 (en) | Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c | |
| EP2436774A3 (en) | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | |
| DE69502380D1 (de) | 4-aminoderivate von 5-substituierten mycophenolsäuren | |
| ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. | |
| BR0317780A (pt) | Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas | |
| WO2002029023A8 (en) | Nicastrin protein | |
| RU2000104127A (ru) | Штамм bacillus subtilis x-15, используемый для профилактики и лечения эндометритов у коров |